Monster Pres sold $1.57m in shares-June 10
https://www.secform4.com/insider-trading/865752.htm
being relieved of them, asset stripping most likely. No way to know for certain who it is but someone is. Many of the tech companies were funded with federal money so those owned at federal level when this is done: Facebook, Twatter, Snap, Instagram- many of those.
Some of these, not all-and not this one trade much less, on average per day. The Walmart ones are a prime example. 7m shares at one price would certainly show up on a chart.
https://www.secform4.com/insider-trading/104169.htm
pension funds are woefully under-funded across the board so that could be a possibility however they also must file paperwork and those not showing up. These going off in the dark-pools as most of the large transactions often do. We'll find out at some point.
I only take the ones that are above the normal amounts according trading plans, except a few where they have so many shares those parameters never met. Morningstar is a good example-has about 22m shares left and fires off sales every few days. That not normal in any measure.
here is that link
https://www.secform4.com/insider-trading/1289419.htm
American in talks for up to 50 Airbus A321XLR jets
PARIS (Reuters) - American Airlines Group Inc is edging toward a deal with Airbus to buy up to 50 newly launched A321XLR extended-range narrow-body aircraft, including some converted from existing orders of other models, people familiar with the matter said.
Airbus and American Airlines declined comment.
The people said the order, if confirmed, could be announced to coincide with the Paris Airshow, which runs through June 23, though officials from the U.S. airline were not expected to attend the show in person.
One of the people said that American Airlines was likely to include the longest-range single-aisle jet in its fleet, but the timing of a decision remained unclear.
American, the world’s largest airline by passenger traffic, has spent over $25 billion in five years to modernize its fleet. It has purchase commitments for 100 aircraft from the A320neo family from 2019, according to its 2018 annual report.
Airbus’ launch of the new A321XLR in Paris came as a blow to rival Boeing Co, which continues to grapple with the global grounding of its top-selling 737 MAX after two deadly crashes.
The new A321XLR has a range of 4,700 nautical miles (8,700 km), nudging it into a long-jump category enjoyed by wide-body jets like Boeing’s out-of-production 757 and eating into a range category that the U.S. planemaker is eyeing with a possible new mid-market twin-aisle jet, the NMA.
But there is a debate over whether passengers will enjoy flying longer distances in medium-haul planes, where cabin pressure may be a concern.
https://www.reuters.com/article/us-france-airshow-airbus-americanair/american-in-talks-for-up-to-50-airbus-a321xlr-jets-sources-idUSKCN1TI2IB?
https://8ch.net/qpro/res/340.html
np anon
or if you don't hold the shares look into long dated put options. Normal shares to short will be hard to come by and if they are available at the retail level there will be a premium attached to acquiring them. A common tactic when a company is obviously overvalued. This IPO was under-priced during the roadshow so it had quite a pop when it began trading.
Crowdstrike files to go public — lost $140 million on $250 million in revenue last year
https://www.cnbc.com/2019/05/14/cybersecurity-firm-crowdstrike-files-to-go-public.html
not solid fundamentals here and then add the fuckery as described in op.
The caveat here is that this company was likely funded through our wonderful 'frens' at the C_A so eventually the feds will own this as with the other examples of this type, the tech comapny's you all know and love.
Do your own research and make your own decisions.
Do not make financial decisions based only on what you see on a public board.
==Blueprint Medicines Co. Director sold $2.25m in shares-June 13th
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Number of employees : 149 people.
https://www.marketscreener.com/BLUEPRINT-MEDICINES-CORP-22033569/company/
https://www.secform4.com/insider-trading/1597264.htm
shareholders meeting tomorrow
Prospect Capital CEO bought $2.6m in shares-June 13
Prospect Capital Corporation is a financial services company. The Company primarily lends to and invests in middle market privately held companies. The Company is a closed-end investment company. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The Company invests primarily in senior and subordinated debt and equity of private companies in need of capital for acquisitions, divestitures, growth, development, recapitalizations and other purposes. The Company makes investments, including lending in private equity sponsored transactions, lending directly to companies not owned by private equity firms, control investments in corporate operating companies, control investments in financial companies, investments in structured credit, real estate investments, investments in syndicated debt, aircraft leasing and online lending. The Company is managed by its investment advisor, Prospect Capital Management L.P.
https://www.marketscreener.com/PROSPECT-CAPITAL-CORPORAT-10554/company/
https://www.secform4.com/insider-trading/1287032.htm